Reprieve Cardiovascular

What Reprieve Cardiovascular does

Reprieve Cardiovascular is a privately held, clinical-stage medical device company developing the Reprieve System, an Intelligent Decongestion Management (IDM) platform for treating Acute Decompensated Heart Failure (ADHF). The system combines continuous real-time urine output monitoring with a proprietary personalized diuretic dose-finding algorithm and titrated saline replacement, aiming to safely accelerate fluid removal while protecting renal function in patients hospitalized with fluid volume overload. The company is targeting the global ADHF population, including over 6.7 million Americans living with heart failure and over 1 million US ADHF hospitalizations annually, where traditional diuretic therapy — unchanged in approach for roughly 60 years — yields average hospital stays of more than five days and 30-day readmission rates of 20-25%.

The Reprieve System is currently investigational only and not commercially available in either the US or the EU; FDA Investigational Device Exemption (IDE) approval was secured in February 2025 for the global FASTR II pivotal trial (up to 400 patients across the US and Europe) following positive FASTR pilot results in 100 randomized patients, published in JACC: Heart Failure. The company has raised approximately $103M in disclosed equity funding (Series A $42M in February 2024 led by Lightstone Ventures and Sante Ventures; Series B $61M in August 2025 led by Deerfield Management) plus additional exempt offerings, and is led by CEO Mark Pacyna (former Medtronic VP & GM of Peripheral Vascular).

Name

Reprieve Cardiovascular

Legal name

Reprieve Cardiovascular, Inc.

Website

https://reprievecardio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Reprieve Cardiovascular is a clinical-stage medical device company developing the Reprieve System, an intelligent decongestion management platform that uses real-time urine output monitoring and personalized diuretic dosing to treat hospitalized acute decompensated heart failure patients.

Ownership category

akta.pro rank

Headquarters

HQ city

Milford

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Reprieve Cardiovascular is developing the Reprieve System, an intelligent decongestion management medical device for treating acute decompensated heart failure. The company is in clinical development stage with the system not yet commercially available. Revenue will be generated from device sales to hospitals upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Reprieve Cardiovascular is developing the Reprieve System, an investigational intelligent decongestion management (IDM) medical device for treating acute decompensated heart failure (ADHF). The system continuously monitors real-time physiological parameters such as urine output and uses a personalized dose-finding algorithm to optimize diuretic dosing, automate saline replacement, and recommend when to escalate or end therapy. The product is currently investigational-only in the US (no commercial sale permitted) and does not yet bear CE marking in the EU/EEA; commercial distribution will follow FDA premarket approval.

Product overview

Reprieve Cardiovascular offers a single unified product, the Reprieve System, which is an intelligent decongestion management (IDM) medical device for treating Acute Decompensated Heart Failure (ADHF). The system combines real-time physiological monitoring with automated dose optimization to personalize diuretic therapy while maintaining kidney function through saline replacement.

Differentiator

Problem solved

Functional benefit

Brands

• Reprieve System: Personalized intelligent decongestion management (IDM) solution for Acute Decompensated Heart Failure patients
• Personalized Volume Management System (PVM)

Products and services

• Reprieve System A personalized intelligent decongestion management (IDM) medical device for treating Acute Decompensated Heart Failure (ADHF) patients in the hospital setting. The system continuously monitors real-time physiological parameters such as urine output and uses a personalized dose-finding algorithm to optimize diuretic therapy and titrate saline replacement, enabling physicians to safely accelerate fluid removal, reduce hospital length of stay, and lower readmission rates. It is intended for hospitals and healthcare systems with cardiovascular and heart failure treatment programs.

Quantifiable outcome

• ~2x faster IV diuretic completion (46 hrs with Reprieve vs 88 hrs with ODT, P = 0.014)
• +6 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Five partnerships are on record, tiered key.

• Tufts Medical Center (Dr. James Udelson)keyStrategic or Co-development Partner · 11 February 2025Dr. James Udelson, Chief of Cardiology and Interim Chief Physician Executive of the CardioVascular Center at Tufts Medical Center, serves as Principal Investigator of the FASTR pilot trial and Chief of the Division of Cardiology. Presented topline results at THT 2025.
• Washington University School of Medicine in St. LouiskeyStrategic or Co-development Partner · 16 December 2024Dr. Ali Javaheri and team at Washington University School of Medicine enrolled the first patient in the FASTR II pivotal study in August 2025. This represents a key clinical trial partnership for the pivotal study.
• TruvetakeyStrategic or Co-development Partner · 2 May 2024Reprieve Cardiovascular partnered with Truveta and leading heart failure researchers to analyze real-world heart failure patient data through the TREAT-AHF study. Truveta provides daily updated, regulatory-grade data from over 100 million de-identified patients across 800+ hospitals and 20,000 clinics in the US. This partnership facilitated the TREAT-AHF analysis and publication demonstrating that heart failure decongestion management has not substantially changed in 20 years.
• Stanford University (Dr. Alexander Sandhu)keyStrategic or Co-development Partner · 2 May 2024Dr. Alexander Sandhu from Stanford University's Division of Cardiovascular Medicine and Stanford Prevention Research Center led the TREAT-AHF study, contributing to understanding contemporary decongestion practices and opportunities to improve patient management paradigm.
• Baylor Scott and White Research InstitutekeyStrategic or Co-development Partner · 2 May 2024Dr. Javed Butler, President of Baylor Scott and White Research Institute and Senior Vice President for Baylor Scott and White Health, serves as Global Principal Investigator of the FASTR II pivotal study, providing strategic leadership for the clinical program.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Edwards Lifesciences: Large-cap medtech with a substantial heart failure portfolio (including structural heart, critical care monitoring, and heart failure diagnostics). Edwards is the type of strategic acquirer or fast-follower that could compete with or absorb a Reprieve System post-approval, and operates in the same hospital cardiology customer set.
• Abbott: Owns the CardioMEMS HF System (implantable pulmonary artery pressure sensor for chronic heart failure management) and a broad cardiovascular device portfolio. Abbott competes for hospital heart failure budget and would be a likely strategic acquirer of a complementary acute-care decongestion platform like Reprieve.
• Medtronic: Diversified medtech with heart failure diagnostics and monitoring solutions (e.g., LindaCare/remote cardiac diagnostics) and a large hospital sales channel. Reprieve's CEO is a former Medtronic VP&GM, making Medtronic a highly relevant strategic acquirer comparable in customer base and channel.
• Boston Scientific: Major cardiovascular device company with heart failure and structural heart franchises and a direct hospital cardiology sales motion. Operates in the same customer segment and would be a comparable strategic acquirer or competitor for hospital heart failure capex budgets.
• Johnson & Johnson (Abiomed): J&J acquired Abiomed (Impella heart pumps) in 2022 to build a heart failure medical device franchise, and Abiomed was an early Reprieve investor. J&J/Abiomed directly addresses acute heart failure in hospitals and is both a natural strategic acquirer and a comparable in the same customer and clinical workflow.

Emerging players

• Vectorious Medical Technologies: Israel-based developer of an implantable left-atrial pressure sensor (V-LAP) for remote heart failure management. Closest emerging peer in heart failure hemodynamic monitoring/dosing technology targeting a similar cardiometabolic disease space as Reprieve.
• FIRE1: Ireland-based medtech developing an implantable sensor for remote heart failure management. Comparable as an early-stage heart failure monitoring/dosing platform competing for hospital and cardiology mindshare with Reprieve's intelligent decongestion concept.
• Procyrion: Houston-based developer of Aortix, a catheter-deployed heart pump for acute decompensated heart failure and cardiogenic shock. Targets the same ADHF patient population as Reprieve but with a mechanical circulatory support rather than fluid-management approach.
• CorWave: France-based developer of a next-generation LVAD using a wave-membrane pump for advanced heart failure. Targets a downstream heart failure population and competes for the same cardiology/cardiothoracic surgery customer set as Reprieve's hospital channel.
• Bodyport: San Francisco-based developer of a connected cardiac biomarker scale for non-invasive heart failure monitoring. Adjacent emerging peer in smart, algorithm-driven heart failure management technology addressing similar value-based-care readmission drivers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/ReprieveCardio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds8 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reprieve Cardiovascular